This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. FDA, and one long-term safety study. The two pivotal programs will enroll approximately 500 patients per study at over 100 sites around the U.S. The primary endpoint of the pivotal studies is the cumulative incidence of gastric ulcers over the six-month treatment period for PA32540 versus 325 mg of enteric-coated aspirin. The long-term study will enroll approximately 400 patients and assess safety over a period of one year. Pozen is developing PA-325/40 for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers. Aspirin is the No. 1 recommended agent for at-risk ...

Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Through this co-marketing agreement, Proven Diagnostics will provide selected diagnostic tools from BHL’s menu of proprietary cardiovascular tests and services which aims at optimizing cardiovascular treatment, these include BHL’s 4myheart cardiovascular disease management program as well.

Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array

...

Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Through this co-marketing agreement, Proven Diagnostics will provide selected diagnostic tools from BHL’s menu of proprietary cardiovascular tests and services which aims at optimizing cardiovascular treatment, these include BHL’s 4myheart cardiovascular disease management program as well.

Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array of clinical laboratory services. These services include microbiology, biochemical and

...

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has announced and presented their new data from the COR diabetes trials for Contrave to expand on top line results announced in July this year. This new data shows that after completing 56 weeks of therapy, Contrave patients have lost weight significantly and improved on important markers of cardiometabolic risk. Though it was good news for investors and analysts, shares dropped a bit and showed no signs of moving upward. The new data was presented during the panel discussion at the 27th Annual Scientific Meeting of The Obesity Society.

Obese patients have a higher risk of developing cardiovascular disease and diabetes. After the Contrave trials patients demonstrated significant improvements in their waist circumference, HDL and triglycerides. Patients with Type 2 diabetes taking Contrave saw a

...

For Immediate Release

Chicago, IL – October 15, 2009 – Zacks Equity Research highlights Sangamo Biosciences, Inc. (SGMO) as the Bull of the Day and Conmed (CNMD) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Intel Corp. (INTC), JPMorgan Chase & Company (JPM) and CSX Corp. (CSX).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

Sangamo Biosciences, Inc. (SGMO) uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases.

We are optimistic about this novel technology. SB-509 has shown some positive results for the treatment of moderate to severe DN. We are also optimistic about other clinical programs. Further, we are impressed by the company's strategy

...

Biomedical company Vivakor Inc. announced today the results of independent, third-party testing of its VivaBlend nutraceutical product. This product is a powerful extract developed by Vivakor scientists and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, the company’s scientists created an optimum blend of super-oxidants, flavonoids and powerful plant phenolics.

The results from third-party testing show that VivaBlend contains a much higher level of antioxidants, phytochemicals and lipophilic antioxidants, from a wider array of plant sources, than its competitors. Lipophilic antioxidants penetrate the lipoprotein cell membrane more easily than other antioxidants and are therefore retained in the body longer (bioactive).

Scientists are still discovering the benefits of these potent natural chemicals in improved health and wellness. Data has shown, however, that different types of antioxidants and phytochemicals collectively may reduce the adverse effects of aging and may lessen the risk of

...

Amarin Corporation plc announced that it had secured financing of $3.0 million in the form of convertible bridge loan notes sold to several institutional investors. The financing consists of a short-term note and warrants, and will allow the company to operate through the end of September 2009.

The notes pay interest at a rate of 8%, mature on September 30, 2009, and are convertible at the option of the holder into the company’s American Depositary Shares. The warrants are for five years and are also convertible into American Depositary Shares based on a price to be determined in the future.

Amarin Corporation plc is attempting to place more permanent financing and has signed a non-binding agreement with several investors for up to $55 million in financing. The company has commitments for a little more than 50% of this amount.

Amarin Corporation plc is a biotechnology company that is

...

We are presenting a list of companies which we believe are currently mispriced, based on our estimate of fair value, by the market. We develop our fair value ranges by projected free cash flow out one year and estimating an appropriate FCF multiple based on our assessment of risk and the strength of the balance sheet.

Cisco Systems [CSCO: 19.57, +0.84 (+4.48%)] Recent Price $17.04 Value Range 21.86 – $38.41 Cisco Systems, Inc. designs, manufactures and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry, and provides services associated with these products and their use. The Company provides a line of products for transporting data, voice, and video within buildings, across campuses, and around the world. Its products are designed to transform how people connect, communicate and collaborate. Cisco Systems, Inc.’s products, which include primarily routers, switches, and products that the

...

For Immediate Release

Chicago, IL – July 13, 2009 – Zacks Equity Research highlights Heinz (HNZ) as the Bull of the Day and Xtent, Inc. (XTNT) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Boeing (BA), Caterpillar (CAT) and Microsoft (MSFT).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day:

Growth in Heinz’s (HNZ) domestic businesses, strengthening international operations, and the reallocation of resources in favor of key brands are major positive trends for the company.

Despite cost pressure from higher commodity costs, strong pricing of 3.5% to 4.5% has allowed the company to report positive earnings surprises in the last twelve quarters. Management expects net sales to increase by 4% to 6% in fiscal 2010 driven by new

...

Headquartered in Menlo Park, California, Xtent Inc. (XTNT) is a development-stage medical device company focused on developing and commercializing its proprietary Custom NX drug eluting stent (DES) Systems to treat coronary artery disease (CAD). We have recently downgraded the stock to a Sell.

The company is most likely to go into liquidation in the next few months. The company’s fundamentals have disappeared and there is virtually nothing left for investors. The company has been burning cash each quarter and has roughly $12 million remaining at the end of first quarter of 2009.

The company received CE mark approval for the CUSTOM NX DES System recently but was unable to commercialize it due to its cash crunch. Xtent also completed a large-scale headcount reduction with only six full-time employees remaining at the end of the first quarter.

Xtent primarily focuses on its development efforts to create Custom NX DES

...